Immunocore Appoints Chairman
News Nov 14, 2013
Dr Knowles succeeds Nicholas Cross who has been Chairman since the company was founded in 2008 and will remain on the Board as Deputy Chairman.
Dr Knowles has been a Non-Executive Director of Immunocore since 2010 and was formerly President of Group Research and a Member of the Executive Committee at F.Hoffman-LaRoche Limited, Basel, Switzerland for 12 years. Dr Knowles also served as a Board member at Genentech Inc. for over ten years and was a Member of the Board of Chugai Pharmaceuticals, Tokyo, Japan. Prior to joining Roche in 1997, he was Research Director, Glaxo Wellcome Europe.
Dr Knowles has also served as Chairman of the Hever Group and the EFPIA Research Directors Group. He was instrumental in creating the Innovative Medicines Initiative (IMI) and was the first Chairman of the Board of IMI (a Joint Undertaking with the EU Commission). He is a Distinguished Professor (FiDiPro) at the University of Helsinki, Finland, holds a visiting chair at the University of Oxford, and is a visiting scholar of Pembroke College, Cambridge.
James Noble, Chief Executive Officer of Immunocore, commented: “We are extremely fortunate to have appointed someone of Jonathan’s calibre as the Executive Chairman of the Immunocore Board. His significant industry experience will support Immunocore as we continue to build our ImmTAC product pipeline and seek further partnerships with pharmaceutical companies. His willingness to commit to Immunocore is a great testament to the potential of our company.
“We would like to take this opportunity to thank Nick Cross for his hard work and significant commitment to Immunocore as Chairman over the past five years. He supported the negotiation of the spin-out from Medigene in 2008 when Immunocore was formed and helped to secure the funding for the company since its inception. He has played an invaluable role in supporting us through our early growth phase, including with our first major commercial agreements, and we are pleased that he will continue to serve as Deputy Chairman.”
Dr Knowles said: “I am delighted to have been appointed as the new Chairman and look forward to working more closely with my Board colleagues and the rest of the team at Immunocore to grow the company, creating novel agents that we hope will contribute significantly to curing cancer.”
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE